FLT3 and acute myeloid leukemia: In relapsed or refractory (R/R) FLT3‐mutated AML, gilteritinib demonstrated high composite complete remission (CRc) rates in both patients previously treated with FLT3 TKIs, such as midostaurin or sorafenib, and in TKI‐naïve patients.